Application of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in the Diagnosis and Evaluation of TIO

• Status: Recruiting
• Trial end date: 2022-03-15
• Target enrollment: 0
• Participant gender: All

Summary

This is an open-label whole-body PET/CT study for investigating the value of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in patients with Tumor-induced osteomalacia.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking Union Medical College Hospital
• Treatments: 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid

Criteria

Inclusion Criteria:

• suspected or confirmed untreated TIO patients;

• 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT within two weeks;

• signed written consent.

Exclusion Criteria:

• pregnancy;

• breastfeeding;

• any medical condition that in the opinion of the investigator may significantly interfere with study compliance.